Cantor Fitzgerald Begins Coverage on Adamas Pharmaceuticals (NASDAQ:ADMS)

Cantor Fitzgerald began coverage on shares of Adamas Pharmaceuticals (NASDAQ:ADMS) in a report issued on Monday morning, BenzingaRatingsTable reports. The brokerage issued a neutral rating and a $8.00 target price on the specialty pharmaceutical company’s stock.

Other equities research analysts also recently issued research reports about the company. Cowen set a $5.00 price objective on Adamas Pharmaceuticals and gave the stock a hold rating in a research report on Friday, August 9th. HC Wainwright lowered their price objective on Adamas Pharmaceuticals from $40.00 to $30.00 and set a buy rating on the stock in a research report on Tuesday, May 28th. Evercore ISI reiterated a buy rating and issued a $55.00 price objective on shares of Adamas Pharmaceuticals in a research report on Monday, August 12th. Zacks Investment Research upgraded Adamas Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, August 13th. Finally, ValuEngine upgraded Adamas Pharmaceuticals from a sell rating to a hold rating in a research report on Thursday, August 1st. One research analyst has rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of $20.43.

Shares of ADMS stock opened at $6.24 on Monday. The company has a debt-to-equity ratio of 3.05, a quick ratio of 7.05 and a current ratio of 7.27. Adamas Pharmaceuticals has a 52-week low of $4.20 and a 52-week high of $22.93. The company has a market capitalization of $168.85 million, a PE ratio of -1.28 and a beta of 1.62. The business’s fifty day moving average is $6.11 and its 200 day moving average is $6.40.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.98) by $0.08. Adamas Pharmaceuticals had a negative return on equity of 149.97% and a negative net margin of 241.41%. The company had revenue of $12.69 million for the quarter, compared to the consensus estimate of $12.62 million. On average, sell-side analysts forecast that Adamas Pharmaceuticals will post -3.74 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quantamental Technologies LLC purchased a new stake in Adamas Pharmaceuticals during the second quarter valued at about $25,000. BNP Paribas Arbitrage SA purchased a new stake in Adamas Pharmaceuticals during the first quarter valued at about $33,000. Advisor Group Inc. raised its position in Adamas Pharmaceuticals by 53.4% during the second quarter. Advisor Group Inc. now owns 11,200 shares of the specialty pharmaceutical company’s stock valued at $69,000 after purchasing an additional 3,900 shares in the last quarter. DekaBank Deutsche Girozentrale raised its position in Adamas Pharmaceuticals by 63.8% during the second quarter. DekaBank Deutsche Girozentrale now owns 15,400 shares of the specialty pharmaceutical company’s stock valued at $91,000 after purchasing an additional 6,000 shares in the last quarter. Finally, Creative Planning purchased a new stake in Adamas Pharmaceuticals during the first quarter valued at about $144,000. Institutional investors and hedge funds own 63.44% of the company’s stock.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

Recommended Story: Does the discount rate affect the economy?

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.